The deal for Gyroscope is Novartis’s first acquisition since it agreed to sell a large stake in Roche back to its crosstown rival for $20.7 billion.
The deal for Gyroscope is Novartis’s first acquisition since it agreed to sell a large stake in Roche back to its crosstown rival for $20.7 billion.
Fintedex delivers real-time news about the financial industry: feature stories, industry developments, opinions plus the latest on people and trends.
© 2021 Fintedex.